Jiang Y - Search Results

1

Potent Hydrazide-Based HDAC Inhibitors with a Superior Pharmacokinetic Profile for Efficient Treatment of Acute Myeloid Leukemia In Vivo.

Jiang Y, Xu J, Yue K, Huang C, Qin M, Chi D, Yu Q, Zhu Y, Hou X, Xu T, Li M, Chou CJ, Li X. Jiang Y, et al. J Med Chem. 2022 Jan 13;65(1):285-302. doi: 10.1021/acs.jmedchem.1c01472. Epub 2021 Dec 23. J Med Chem. 2022. PMID: 34942071

2

Design, synthesis and biological evaluation of novel L-isoserine tripeptide derivatives as aminopeptidase N inhibitors.

Pan H, Yang K, Zhang J, Xu Y, Jiang Y, Yuan Y, Zhang X, Xu W. Pan H, et al. Among authors: jiang y. J Enzyme Inhib Med Chem. 2013 Aug;28(4):717-26. doi: 10.3109/14756366.2012.680062. Epub 2012 Apr 30. J Enzyme Inhib Med Chem. 2013. PMID: 22545941 Free article.

3

Progress of HDAC inhibitor panobinostat in the treatment of cancer.

Li X, Zhang J, Xie Y, Jiang Y, Yingjie Z, Xu W. Li X, et al. Among authors: jiang y. Curr Drug Targets. 2014 Jun;15(6):622-34. doi: 10.2174/1389450115666140306152642. Curr Drug Targets. 2014. PMID: 24597570 Review.

4

Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.

Li X, Inks ES, Li X, Hou J, Chou CJ, Zhang J, Jiang Y, Zhang Y, Xu W. Li X, et al. Among authors: jiang y. J Med Chem. 2014 Apr 24;57(8):3324-41. doi: 10.1021/jm401877m. Epub 2014 Apr 15. J Med Chem. 2014. PMID: 24694055 Free PMC article.

5

Design, synthesis and preliminary evaluation of α-sulfonyl γ-(glycinyl-amino)proline peptidomimetics as matrix metalloproteinase inhibitors.

Zhang J, Li X, Jiang Y, Feng J, Li X, Zhang Y, Xu W. Zhang J, et al. Among authors: jiang y. Bioorg Med Chem. 2014 Jun 1;22(11):3055-64. doi: 10.1016/j.bmc.2013.12.025. Epub 2013 Dec 21. Bioorg Med Chem. 2014. PMID: 24755524

6

Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy.

Zhang L, Han Y, Jiang Q, Wang C, Chen X, Li X, Xu F, Jiang Y, Wang Q, Xu W. Zhang L, et al. Among authors: jiang q, jiang y. Med Res Rev. 2015 Jan;35(1):63-84. doi: 10.1002/med.21320. Epub 2014 Apr 29. Med Res Rev. 2015. PMID: 24782318 Review.

7

Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.

Li X, Hou J, Li X, Jiang Y, Liu X, Mu W, Jin Y, Zhang Y, Xu W. Li X, et al. Among authors: jiang y. Eur J Med Chem. 2015 Jan 7;89:628-37. doi: 10.1016/j.ejmech.2014.10.077. Epub 2014 Oct 29. Eur J Med Chem. 2015. PMID: 25462271

8

Discovery of Multi-target Anticancer Agents Based on HDAC Inhibitor MS-275 and 5-FU.

Jiang Y, Li X, Li X, Hou J, Ding Y, Zhang J, Xu W, Zhang Y. Jiang Y, et al. Med Chem. 2016;12(1):30-6. doi: 10.2174/1573406411666150714111045. Med Chem. 2016. PMID: 26711240

9

LJNK, an indoline-2,3-dione-based aminopeptidase N inhibitor with promising antitumor potency.

Hou J, Jin K, Li J, Jiang Y, Li X, Wang X, Huang Y, Zhang Y, Xu W. Hou J, et al. Among authors: jiang y. Anticancer Drugs. 2016 Jul;27(6):496-507. doi: 10.1097/CAD.0000000000000351. Anticancer Drugs. 2016. PMID: 26872309

10

Design, synthesis, and biological characterization of tamibarotene analogs as anticancer agents.

Jiang Y, Li X, Wang X, Wang Z, Zhang J, Wu J, Xu W. Jiang Y, et al. Chem Biol Drug Des. 2016 Oct;88(4):542-55. doi: 10.1111/cbdd.12778. Epub 2016 Jun 1. Chem Biol Drug Des. 2016. PMID: 27113097

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45,168 results

Search Page

Filters